Skip to main content

Table 1 Patients' characteristics at baseline

From: Prospective evaluation of bone markers, parathormone and 1,25-(OH)2 vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz

Variable

N(%)

Age, years [mean (SD)]

41.6 (11.9)

Males

61 (81.3)

Risk factor IVDU

6 (8)

BMI (< 25 Kg/m2)

39 (52.7)

Viral load > 100.000 copies/mL

26 (34.7)

CD4 T cell count < 200 cells/mm3

17 (22.7)

CD4/CD8 ratio < 0.4

42 (56)

Cigarette smokers

35 (46.7)

HCV Ab positive

11 (14.7)

CDC 93 clinical class A

46 (65.7)

HAART:

 

   • TDF/FTC + EFV

33 (44)

   • TDF/FTC + ATV/r

42 (56)

Phosphoraemia < 2.7 mg/dL

19 (25.3)

1,25 (OH)2 Vitamin D < 11 pg/mL

19 (25.3)

Hyperparathyroidism (> 65 pg/mL)

4 (5.3)

eGFR creatinine * < 90 mL/min

26 (34.6)

eGFR cystatin C * < 90 mL/min

15 (20.5)

OC, ng/mL [mean (SD)]

19.86 (10)

CTx, ng/mL [mean (SD)]

0.43 (0.26)

OPG, ng/mL [mean (SD)]

0.83 (0.41)

  1. N number, SD standard deviation, IVDU intra-venous drug users, BMI body mass index, HAART highly active antiretroviral therapy, TDF tenofovir, FTC emtricitabine, EFV efavirenz, ATV/r atazanavir/ritonavir, eGFR estimated glomerular filtration rate, OC osteocalcin, CTx C-terminal cross-laps, OPG osteoprotegerin
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us